About: Multiplex PCR point of care testing versus routine, laboratory-based testing in the treatment of adults with respiratory tract infections: a quasi-randomised study assessing impact on length of stay and antimicrobial use

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Multiplex PCR point of care testing versus routine, laboratory-based testing in the treatment of adults with respiratory tract infections: a quasi-randomised study assessing impact on length of stay and antimicrobial use Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Multiplex PCR point of care testing versus routine, laboratory-based testing in the treatment of adults with respiratory tract infections: a quasi-randomised study assessing impact on length of stay and antimicrobial use
Creator	Andrews, Denise Chetty, Yumela Jeyaratnam, Dakshika Letters, Andrew Sudhanva, Malur Virk, Manjinder Cooper, Ben Glass, Stephen Kelly, Philip
Source	Medline; PMC
abstract	BACKGROUND: Laboratory-based respiratory pathogen (RP) results are often available too late to influence clinical decisions such as hospitalisation or antibiotic treatment due to time delay in transport of specimens and testing schedules. Ward-based i.e. point of care (POC) testing providing rapid results may alter the clinical management pathway. METHODS: FilmArray® RP polymerase chain reaction (PCR) systems were placed in three in-patient and out-patient medical areas. Patients presenting with influenza-like illness /upper respiratory tract infection +/− lower RTI were recruited between January–July 2015. FilmArray® POC testing occurred on even days of the month (intervention) or routine, laboratory-based RP PCR testing +/− atypical serology on odd days (control). The primary outcome was length of hospital stay. The secondary outcomes were impact on the use of antimicrobials, readmissions, all-cause mortality, length of ward stay and turn-around time (TAT) (time to result from admission). RESULTS: Of 606 eligible patients, 545 (89.9%) were included; 211 in the control arm and 334 in the intervention arm. 20% of control arm patients and 24% of intervention arm patients had an RP detected. POC testing was not associated with the primary outcome measure, length of stay, but reduced the TAT from 39.5 h to 19.0 h, p < 0.001. Only the prescribing decision differed between study arms, p < 0.001. When antivirals were given, the intervention was associated with a reduction in the median time to the first dose of 36 h and allowed appropriate treatment of mycoplasma infection. CONCLUSIONS: We found no association between respiratory PCR POC testing and length of stay or most of the secondary outcomes except the antimicrobial prescribing decision. This was probably due to a delay in initiating FilmArray® testing. Despite this, POC testing allowed time-critical antivirals to be given significantly faster, appropriate mycoplasma treatment and results were available considerably faster than routine, laboratory-based testing. Ward-staff of all grades performed POC testing without difficulty suggesting potential use across many divergent healthcare settings. Further studies evaluating the implementation of rapid respiratory PCR POC testing and the effect on length of stay and antimicrobial use are required. TRIAL REGISTRATION: ISRCTN10470967, Retrospectively Registered, 30/6/2015.
has issue date	2017-10-10(xsd:dateTime)
bibo:doi	10.1186/s12879-017-2784-z
bibo:pmid	29017451
has license	cc-by
sha1sum (hex)	e33495040bf8950cd13d754656a31f9b9bdad01d
schema:url	https://doi.org/10.1186/s12879-017-2784-z
resource representing a document's title	Multiplex PCR point of care testing versus routine, laboratory-based testing in the treatment of adults with respiratory tract infections: a quasi-randomised study assessing impact on length of stay and antimicrobial use
has PubMed Central identifier	PMC5635493
has PubMed identifier	29017451
schema:publication	BMC Infect Dis
resource representing a document's body	covid:e33495040bf8950cd13d754656a31f9b9bdad01d#body_text
is schema:about of	named entity 'ASSESSING' named entity 'BASED' named entity 'POC' named entity 'adults' named entity 'Multiplex PCR' named entity 'USE' named entity 'RESPIRATORY TRACT INFECTIONS' named entity 'IMPACT' named entity 'MULTIPLEX PCR' named entity 'ANTIMICROBIAL' named entity 'BASED' named entity 'CLINICAL MANAGEMENT' named entity 'PROVIDING' named entity 'PATHWAY' named entity 'INFLUENCE' named entity 'SPECIMENS' named entity 'DUE TO' named entity 'ANTIBIOTIC TREATMENT' named entity 'PATHOGEN' named entity 'DECISIONS' named entity 'TREATMENT' named entity 'RESPIRATORY' named entity 'SCHEDULES' named entity 'TIME DELAY' named entity 'LABORATORY' named entity 'QUASI-RANDOMISED STUDY' named entity 'POINT OF CARE TESTING' named entity 'LENGTH OF STAY' named entity 'ADULTS' named entity 'TESTING' named entity 'TRANSPORT' named entity 'RESULTS' named entity 'ALTER' named entity 'TOO LATE' named entity 'LABORATORY' named entity 'POINT OF CARE' named entity 'WARD' named entity 'RAPID' named entity 'BACKGROUND' named entity 'AVAILABLE' named entity 'CLINICAL' named entity 'TESTING' named entity 'ROUTINE' named entity 'HOSPITALISATION' covid:arg/e33495040bf8950cd13d754656a31f9b9bdad01d named entity 'antibiotic' named entity 'antimicrobial' named entity 'virus' named entity 'teicoplanin' named entity 'viruses' named entity 'antibiotic treatment' named entity 'POC' named entity 'antimicrobial' named entity 'respiratory tract infections' named entity 'length of stay' named entity 'TAT' named entity '3.5' named entity 'binomial regression' named entity 'Antibiotics' named entity 'CURB-65 score' named entity '5.2' named entity 'infection control' named entity 'RSV' named entity 'antibiotics' named entity 'Italy' named entity 'antibiotics' named entity 'adenovirus' named entity 'CFT' named entity 'urinary tract infection' named entity 'type 2' named entity 'missing data' named entity 'hospital Trust' named entity 'pneumonia'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software